Fresenius Biotech obtains reimbursement approval for Removab® antibody in Belgium
04.10.2011
more
Removab® receives approval for a shorter infusion time in treating malignant ascites – one-year survival rate in Removab®-treated patients is more than four times higher
20.09.2011
more
Fresenius Biotech obtains reimbursement approval for Removab® antibody in Italy
22.06.2011
more
ASCO 2011: Fresenius Biotech presents new data for the trifunctional antibody Removab® − benefit in overall survival of cancer patients demonstrated
07.06.2011
more
Fresenius Biotech’s ATG-Fresenius S approved in Austria for GVHD prophylaxis in stem cell transplantations
06.06.2011
more
Fresenius Biotech’s ATG-Fresenius S approved for GVHD prophylaxis in stem cell transplantations in Germany
07.03.2011
Fresenius Biotech is the first company in Germany to receive Paul-Ehrlich-Institut approval to use a polyclonal antibody in stem cell transplantations.
more
Fresenius Biotech announces agreement with Swedish Orphan Biovitrum for distribution of Removab®
27.01.2011
more
Removab® (Catumaxomab) wins Galenus-von-Pergamon award
21.10.2010
more
Fresenius Biotech presents new data on trifunctional antibody Removab® at 46th ASCO Annual Meeting in Chicago
07.06.2010
The data show that overall survival significantly improved in patients who exhibit an early immune reaction subsequent to Removab®
treatment.
more
Fresenius Biotech launches new corporate website
07.01.2010
more
Removab® receives marketing approval
23.04.2009
European Commission grants marketing authorization for Removab®
more
EMEA Committee recommends marketing approval
18.02.2009
The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval of Removab for the intraperitoneal treatment of malignant ascites.
more
Removab Phase II Gastric
23.12.2008
Phase II study shows trifunctional antibody Removab® (catumaxomab) well tolerated in treatment of gastric cancer
more
Removab Application for Marketing Authorization
21.12.2007
Fresenius Biotech applies for the marketing authorization of the trifunctional antibody Removab® for the treatment of malignant ascites
more
Removab Phase II-III MA
17.07.2007
Secondary endpoints of phase II/III study confirm clear benefits from treatment with Removab® for patients with malignant ascites
more
Removab Phase II-III
22.03.2007
Phase II/III pivotal study with trifunctional antibody Removab® shows encouraging results in malignant ascites from various cancers
more
